HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Online retailer files for public offering of up to 6 mil. shares of common stock with the Securities & Exchange Commission Feb. 9. Drugstore.com is offering 4.5 mil. shares of common stock with selling stockholders offering 1.5 mil. shares. Underwriters Morgan Stanley Dean Witter, Donaldson, Lufkin & Jenrette Securities Corp., Salomon Smith Barney and Thomas Weisel Partners, may be granted an option to purchase up to an aggregate of 903,000 additional shares. The e-tailer opened its first day of trading July 28 (1"The Rose Sheet" Aug. 2, 1999, In Brief)

You may also be interested in...


Trading opened at $18 per share for 5 mil. shares July 28, and reached a high of 70 before closing at 50-1/4. The online retailer filed its initial public offering in May, with the expectation of raising $67.5 mil. (1"The Rose Sheet" May 31, In Brief). The offering was managed by Morgan Stanley Dean Witter, Donaldson, Lufkin & Jenrette and Thomas Weisel Partners

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts